Pharmacological approach to acute pancreatitis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Pharmacological approach to acute pancreatitis. / Bang, U.C.; Semb, S.; Nøjgaard, Camilla; Bendtsen, F.; Bang, Ulrich-Christian; Semb, Synne; Nojgaard, Camilla; Bendtsen, Flemming.

I: World Journal of Gastroenterology, Bind 14, Nr. 19, 2008, s. 2968-76.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Bang, UC, Semb, S, Nøjgaard, C, Bendtsen, F, Bang, U-C, Semb, S, Nojgaard, C & Bendtsen, F 2008, 'Pharmacological approach to acute pancreatitis' World Journal of Gastroenterology, bind 14, nr. 19, s. 2968-76. https://doi.org/https://doi.org/10.3748/, https://doi.org/10.3748/

APA

Bang, U. C., Semb, S., Nøjgaard, C., Bendtsen, F., Bang, U-C., Semb, S., ... Bendtsen, F. (2008). Pharmacological approach to acute pancreatitis. World Journal of Gastroenterology, 14(19), 2968-76. https://doi.org/https://doi.org/10.3748/, https://doi.org/10.3748/

Vancouver

Bang UC, Semb S, Nøjgaard C, Bendtsen F, Bang U-C, Semb S o.a. Pharmacological approach to acute pancreatitis. World Journal of Gastroenterology. 2008;14(19):2968-76. https://doi.org/https://doi.org/10.3748/, https://doi.org/10.3748/

Author

Bang, U.C. ; Semb, S. ; Nøjgaard, Camilla ; Bendtsen, F. ; Bang, Ulrich-Christian ; Semb, Synne ; Nojgaard, Camilla ; Bendtsen, Flemming. / Pharmacological approach to acute pancreatitis. I: World Journal of Gastroenterology. 2008 ; Bind 14, Nr. 19. s. 2968-76.

Bibtex

@article{99169c50059711deb05e000ea68e967b,
title = "Pharmacological approach to acute pancreatitis",
abstract = "The aim of the present review is to summarize the current knowledge regarding pharmacological prevention and treatment of acute pancreatitis (AP) based on experimental animal models and clinical trials. Somatostatin (SS) and octreotide inhibit the exocrine production of pancreatic enzymes and may be useful as prophylaxis against post endoscopic retrograde cholangiopancreatography pancreatitis (PEP). The protease inhibitor gabexate mesilate (GM) is used routinely as treatment to AP in some countries, but randomized clinical trials and a meta-analysis do not support this practice. Nitroglycerin (NGL) is a nitrogen oxide (NO) donor, which relaxes the sphincter of Oddi. Studies show conflicting results when applied prior to ERCP and a large multicenter randomized study is warranted. Steroids administered as prophylaxis against PEP has been validated without effect in several randomized trials. The non-steroidal anti-inflammatory drugs (NSAID) indomethacin and diclofenac have in randomized studies showed potential as prophylaxis against PEP. Interleukin 10 (IL-10) is a cytokine with anti-inflammatory properties but two trials testing IL-10 as prophylaxis to PEP have returned conflicting results. Antibodies against tumor necrosis factor-alpha (TNF-alpha) have a potential as rescue therapy but no clinical trials are currently being conducted. The antibiotics beta-lactams and quinolones reduce mortality when necrosis is present in pancreas and may also reduce incidence of infected necrosis. Evidence based pharmacological treatment of AP is limited and studies on the effect of potent anti-inflammatory drugs are warranted.",
author = "U.C. Bang and S. Semb and Camilla N{\o}jgaard and F. Bendtsen and Ulrich-Christian Bang and Synne Semb and Camilla Nojgaard and Flemming Bendtsen",
year = "2008",
doi = "http://dx.doi.org/http://dx.doi.org/10.3748/",
language = "English",
volume = "14",
pages = "2968--76",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "Baishideng Publishing Group Co., Limited",
number = "19",

}

RIS

TY - JOUR

T1 - Pharmacological approach to acute pancreatitis

AU - Bang, U.C.

AU - Semb, S.

AU - Nøjgaard, Camilla

AU - Bendtsen, F.

AU - Bang, Ulrich-Christian

AU - Semb, Synne

AU - Nojgaard, Camilla

AU - Bendtsen, Flemming

PY - 2008

Y1 - 2008

N2 - The aim of the present review is to summarize the current knowledge regarding pharmacological prevention and treatment of acute pancreatitis (AP) based on experimental animal models and clinical trials. Somatostatin (SS) and octreotide inhibit the exocrine production of pancreatic enzymes and may be useful as prophylaxis against post endoscopic retrograde cholangiopancreatography pancreatitis (PEP). The protease inhibitor gabexate mesilate (GM) is used routinely as treatment to AP in some countries, but randomized clinical trials and a meta-analysis do not support this practice. Nitroglycerin (NGL) is a nitrogen oxide (NO) donor, which relaxes the sphincter of Oddi. Studies show conflicting results when applied prior to ERCP and a large multicenter randomized study is warranted. Steroids administered as prophylaxis against PEP has been validated without effect in several randomized trials. The non-steroidal anti-inflammatory drugs (NSAID) indomethacin and diclofenac have in randomized studies showed potential as prophylaxis against PEP. Interleukin 10 (IL-10) is a cytokine with anti-inflammatory properties but two trials testing IL-10 as prophylaxis to PEP have returned conflicting results. Antibodies against tumor necrosis factor-alpha (TNF-alpha) have a potential as rescue therapy but no clinical trials are currently being conducted. The antibiotics beta-lactams and quinolones reduce mortality when necrosis is present in pancreas and may also reduce incidence of infected necrosis. Evidence based pharmacological treatment of AP is limited and studies on the effect of potent anti-inflammatory drugs are warranted.

AB - The aim of the present review is to summarize the current knowledge regarding pharmacological prevention and treatment of acute pancreatitis (AP) based on experimental animal models and clinical trials. Somatostatin (SS) and octreotide inhibit the exocrine production of pancreatic enzymes and may be useful as prophylaxis against post endoscopic retrograde cholangiopancreatography pancreatitis (PEP). The protease inhibitor gabexate mesilate (GM) is used routinely as treatment to AP in some countries, but randomized clinical trials and a meta-analysis do not support this practice. Nitroglycerin (NGL) is a nitrogen oxide (NO) donor, which relaxes the sphincter of Oddi. Studies show conflicting results when applied prior to ERCP and a large multicenter randomized study is warranted. Steroids administered as prophylaxis against PEP has been validated without effect in several randomized trials. The non-steroidal anti-inflammatory drugs (NSAID) indomethacin and diclofenac have in randomized studies showed potential as prophylaxis against PEP. Interleukin 10 (IL-10) is a cytokine with anti-inflammatory properties but two trials testing IL-10 as prophylaxis to PEP have returned conflicting results. Antibodies against tumor necrosis factor-alpha (TNF-alpha) have a potential as rescue therapy but no clinical trials are currently being conducted. The antibiotics beta-lactams and quinolones reduce mortality when necrosis is present in pancreas and may also reduce incidence of infected necrosis. Evidence based pharmacological treatment of AP is limited and studies on the effect of potent anti-inflammatory drugs are warranted.

U2 - http://dx.doi.org/http://dx.doi.org/10.3748/

DO - http://dx.doi.org/http://dx.doi.org/10.3748/

M3 - Journal article

VL - 14

SP - 2968

EP - 2976

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 19

ER -

ID: 10905671